Existing backer GV returned to take part in a $100m round for the clinical data software provider that also attracted new investor Regeneron Pharmaceuticals.
US-based health informatics technology developer DNAnexus closed a $100m funding round yesterday backed by biotechnology firm Regeneron Pharmaceuticals and GV, an early-stage investment subsidiary of internet and technology conglomerate Alphabet.
Investment management firm Perceptive Advisors and venture capital firm Northpond Ventures co-led the round, which also featured Foresite Capital, TPG Capital and First Round Capital.
Founded in 2009, DNAnexus has created a software platform that enables researchers to store, analyse, manage and collaborate on large amounts of complex clinical data…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
